122 related articles for article (PubMed ID: 24928032)
1. Mortality in Parkinson's disease is not associated with the severity of early dopaminergic defect.
Järvelä JT; Rinne JO; Eskola O; Kaasinen V
Parkinsonism Relat Disord; 2014 Aug; 20(8):894-7. PubMed ID: 24928032
[TBL] [Abstract][Full Text] [Related]
2. Seasonality of striatal dopamine synthesis capacity in Parkinson's disease.
Kaasinen V; Jokinen P; Joutsa J; Eskola O; Rinne JO
Neurosci Lett; 2012 Nov; 530(1):80-4. PubMed ID: 23041046
[TBL] [Abstract][Full Text] [Related]
3. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
[TBL] [Abstract][Full Text] [Related]
4. Comparative assessment of 6-[
Becker G; Bahri MA; Michel A; Hustadt F; Garraux G; Luxen A; Lemaire C; Plenevaux A
J Neurochem; 2017 May; 141(4):626-635. PubMed ID: 28294334
[TBL] [Abstract][Full Text] [Related]
5. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.
Whone AL; Watts RL; Stoessl AJ; Davis M; Reske S; Nahmias C; Lang AE; Rascol O; Ribeiro MJ; Remy P; Poewe WH; Hauser RA; Brooks DJ;
Ann Neurol; 2003 Jul; 54(1):93-101. PubMed ID: 12838524
[TBL] [Abstract][Full Text] [Related]
6. Survival in Parkinson's disease in relation to striatal dopamine transporter binding.
Mäkinen E; Joutsa J; Vahlberg T; Kaasinen V
Parkinsonism Relat Disord; 2017 Sep; 42():66-72. PubMed ID: 28662820
[TBL] [Abstract][Full Text] [Related]
7. Dopaminergic correlates of metabolic network activity in Parkinson's disease.
Holtbernd F; Ma Y; Peng S; Schwartz F; Timmermann L; Kracht L; Fink GR; Tang CC; Eidelberg D; Eggers C
Hum Brain Mapp; 2015 Sep; 36(9):3575-85. PubMed ID: 26037537
[TBL] [Abstract][Full Text] [Related]
8. Levodopa pharmacokinetic-pharmacodynamic modeling and 6-[18F]levodopa positron emission tomography in patients with Parkinson's disease.
Dietz M; Harder S; Graff J; Künig G; Vontobel P; Leenders KL; Baas H
Clin Pharmacol Ther; 2001 Jul; 70(1):33-41. PubMed ID: 11452242
[TBL] [Abstract][Full Text] [Related]
9. Striatal FDOPA uptake and cognition in advanced non-demented Parkinson's disease: a clinical and FDOPA-PET study.
van Beilen M; Portman AT; Kiers HA; Maguire RP; Kaasinen V; Koning M; Pruim J; Leenders KL
Parkinsonism Relat Disord; 2008; 14(3):224-8. PubMed ID: 18249027
[TBL] [Abstract][Full Text] [Related]
10. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET.
Ishikawa T; Dhawan V; Kazumata K; Chaly T; Mandel F; Neumeyer J; Margouleff C; Babchyck B; Zanzi I; Eidelberg D
J Nucl Med; 1996 Nov; 37(11):1760-5. PubMed ID: 8917170
[TBL] [Abstract][Full Text] [Related]
11. Striatal dopaminergic activity (FDOPA-PET) associated with cognitive items of a depression scale (MADRS) in Parkinson's disease.
Koerts J; Leenders KL; Koning M; Portman AT; van Beilen M
Eur J Neurosci; 2007 May; 25(10):3132-6. PubMed ID: 17561826
[TBL] [Abstract][Full Text] [Related]
12. Striatal dopamine loss and discriminative sensory dysfunction in Parkinson's disease.
Lyoo CH; Ryu YH; Lee MJ; Lee MS
Acta Neurol Scand; 2012 Nov; 126(5):344-9. PubMed ID: 22380639
[TBL] [Abstract][Full Text] [Related]
13. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
Rinne OJ; Nurmi E; Ruottinen HM; Bergman J; Eskola O; Solin O
Synapse; 2001 Jun; 40(3):193-200. PubMed ID: 11304757
[TBL] [Abstract][Full Text] [Related]
14. Crossover study of (99m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in Parkinson's disease patients.
Huang WS; Chiang YH; Lin JC; Chou YH; Cheng CY; Liu RS
J Nucl Med; 2003 Jul; 44(7):999-1005. PubMed ID: 12843212
[TBL] [Abstract][Full Text] [Related]
15. Corticostriatal covariance patterns of 6-[18F]fluoro-L-dopa and [18F]fluorodeoxyglucose PET in Parkinson's disease.
Kaasinen V; Maguire RP; Hundemer HP; Leenders KL
J Neurol; 2006 Mar; 253(3):340-8. PubMed ID: 16222426
[TBL] [Abstract][Full Text] [Related]
16. Comparison of [18F]FDOPA, [18F]FMT and [18F]FECNT for imaging dopaminergic neurotransmission in mice.
Honer M; Hengerer B; Blagoev M; Hintermann S; Waldmeier P; Schubiger PA; Ametamey SM
Nucl Med Biol; 2006 Jul; 33(5):607-14. PubMed ID: 16843835
[TBL] [Abstract][Full Text] [Related]
17. Apathy and striatal dopamine defects in non-demented patients with Parkinson's disease.
Chung SJ; Lee JJ; Ham JH; Lee PH; Sohn YH
Parkinsonism Relat Disord; 2016 Feb; 23():62-5. PubMed ID: 26717857
[TBL] [Abstract][Full Text] [Related]
18. Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease.
Kuwabara H; Cumming P; Yasuhara Y; Léger GC; Guttman M; Diksic M; Evans AC; Gjedde A
J Nucl Med; 1995 Jul; 36(7):1226-31. PubMed ID: 7790948
[TBL] [Abstract][Full Text] [Related]
19. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET.
Nurmi E; Bergman J; Eskola O; Solin O; Vahlberg T; Sonninen P; Rinne JO
Synapse; 2003 Jun; 48(3):109-15. PubMed ID: 12645035
[TBL] [Abstract][Full Text] [Related]
20. Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study.
Brück A; Aalto S; Nurmi E; Vahlberg T; Bergman J; Rinne JO
Mov Disord; 2006 Jul; 21(7):958-63. PubMed ID: 16550545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
